Batteries Included? The Power Potential of Human Electric Current Now. Powered by – Now. Powered by Northrop Grumman.

Maybe were all just batteries. Thats the bad news for Keanu Reeves Neo, who wakes up from a chemically-induced slumber and discovers hes nothing more than a pack of double-As connected to a massive power station run by evil robot overlords in the dystopian sci-fi film The Matrix.

But what if the power potential of human electric current wasnt so post-apocalyptic? As the International Energy Agency notes, global demand for power rose 2.3% in 2018, which represents the biggest increase in the last decade. Ever since Ben Franklin first decided that flying kites in dangerous weather was solid scientific practice, humans have been finding new ways to use electricity and discovering that demand never stops.

The bad news? Youre no coppertop. The better news? Bioelectricity is essential to life and may drive the future of human development.

Harvesting electricity from human activity is nothing new. As Knowable Magazine notes, breathing can produce more than 0.80 watts, body heat can generate up to 4.8 watts, and the motion of your arms creates a stunning 60 watts of power.

But the notion of electricity as fundamental to biological life isnt quite so clear-cut. According to Quartz, while there were some experiments measuring human electrical currents in the mid-1920s, its wasnt until 1949 that Alan Hodgkin and Andrew Huxley identified the movement of ions across cell nerve membranes. The pair took home a Nobel Prize for their work, but this electric revolution was quickly outpaced by the double-helix discovery of DNA. For decades, genes became the best-fit scientific foundation for biology, while electricity research was short-circuited.

Then, in 1976, Erwin Neher and Bert Sakmann developed a tool capable of circumventing bioelectricitys biggest problem: studying ion movements without killing their cellular transport mediums. And later, in 2012, Richard Nuccitelli created a device sensitive and subtle enough to track human electric currents on skin, and discovered that, when skin cells are wounded, they emit an injury current that calls for help from other cells. The larger the wound, the bigger the current and the current decreases with age. Other work found that charges inside embryo cells significantly affected development. As NOVA states, Researchers overwhelmingly agree that bioelectric currents are essential to nerve and muscle function.

With the human nervous system constantly generating a fluctuating electric current, why cant we all just plug in and power up? It all comes down to the two halves of electric potential: positive and negative charges.

The electricity were most familiar with the kind Franklin flew kites for and that powers our smartphones, dishwashers and light bulbs depends on the flow of negatively-charged electrons to produce a current. Meanwhile, in our bodies, its the movement of positively-charged ions such as potassium, sodium and calcium passing through cell membranes that create electric potential. And while this variable voltage is essential to keep hearts beating, limbs moving and minds functioning, its not great for typical electrical applications. For example, when animal cells take in sodium and chloride ions and discharge potassium ions, the result is a voltage between -40 to -80 mV across membranes, significantly less than a single watch battery.

However, as it turns out, human electric current offers significant potential for internal applications.

The biggest potential for human-produced power? Improved healing. Studies published in the journal Advances in Wound Care have shown that supplementing the bodys electric current with outside electrical stimulation can help to reduce the recovery time needed for bedsores, which are some of the most difficult wounds to mitigate, let alone fully heal. Similar work has shown improvements in healing bone fractures.

Next on the list? Cancer. While research in the 1920s demonstrated a connection between changing electric gradients and cancerous tumors, cell mutations are the most commonly cited cause of cancer concerns. Now, theres speculation that misregulation of electric currents may lead to cellular communication challenges in effect, cells forget theyre part of a larger network and begin acting selfishly by hoarding resources and growing out of control. Research from the University of Nottingham found that biologically-generated currents underpin specific cancer cell behaviors, and new techniques using a combination of gene therapy and light-activated ion channels have seen success treating cancer in tadpoles.

However, despite steady progress, challenges remain. Human genomes are far more complex than those of rats or tadpoles, and gene therapies face significant regulatory challenges. Electric treatments for wound healing also struggle with standardization how long should currents be applied to wounds for maximum effect without causing secondary damage? At what voltage? Using what type of device? Is alternating current (AC) or direct current (DC) safer? More effective?

The result is a kind of cautious optimism. While bioelectric benefits are grounded in solid science, more testing and research is necessary to standardize and streamline medical processes.

Bioelectric research offers the tantalizing potential to tap the inherent power of the human nervous system, but were not there yet.

Still, theres good reason to be optimistic. Mike Levin of Tufts University, whose lab is on the leading edge of human electric current research, puts it simply: Understanding the bioelectricity, biomechanics, and transcriptional circuits that allow cells to cooperate toward large-scale goals is the key to regenerative medicine, birth defects, cancer reprogramming, aging, synthetic bioengineering, and even new AI.

Put simply? Were not batteries thanks to positive bioelectric potential, were even better.

Read more here:
Batteries Included? The Power Potential of Human Electric Current Now. Powered by - Now. Powered by Northrop Grumman.

Reception to open Magnificent Birds show – The Greater New Milford Spectrum

Published 12:00am EST, Friday, February 14, 2020

Sherman Library will open an exhibit, Magnificent Birds, with a reception Feb. 21 from 6 to 7:30 p.m.

The show, which will feature photographs by Jeff Ginsburg and Lu Li, will include an artist talk March 14 at 1 p.m.

The show will run through April 1.

Growing up in very different worlds, Ginsburg and Li both share a love of travel, nature and photography.

As a little girl, Li began her fascination with cameras, rare commodities in China.

Nevertheless, after years of saving, she succeeded and was able to travel and photograph the exotic lands of China during college breaks.

Li earned a bachelors degree in radar engineering from Chinas top engineering college and then became the first female to lead a major development team at the Chinese Navys Research Institute.

Li earned a masters degree in Computer Science at CUNY and implemented next generation cell phone systems.

I think the camera often produces images more compelling than the actual subject, Li said. I love spending hours quietly watching and recording my wild ducks and birds.

In fact, I feel Im one of them through my adoration and feelings of strong connection, she said. I think my photos capture their indescribable beauty.

Ginsburg grew up in Danbury and has been creatively improving photographs since building a basement darkroom when he was 11 years old.

He earned a bachelors degree in bioengineering at Duke University and while there worked for four years as the photographer for their daily paper, developing all his prints in their darkrooms and completing a rigorous photography course.

He then received a masters degree in electrical engineering at Washington University St. Louis and then worked in Boston as a biomedical engineer in research and development.

Later, he moved to Manhattan to create a reporting system at Morgan Stanley.

I believe every photo must have an emotional impact, said Ginsburg when asked what his guiding principle has been throughout his years of photography.

Now retired, they live in the woods on Squantz Pond and enjoy traveling to many countries and national parks.

Li enjoys photographing, learning French and playing the cello.

Li has just returned from the National Tennis Championships (amateurs over 40), beating her singles opponents with almost perfect scores.

Ginsburg enjoys photographing, sailing, playing tennis, and creative writing.

One of his prints was displayed at Dukes Nasher Art Museum.

His photo, Food Under Foot, won first prize at Great Hollow Juried Art Show 2018.

For more information about the show, call the Sherman Center library at 860-354-2455.

Read the original:
Reception to open Magnificent Birds show - The Greater New Milford Spectrum

The Love & Hate Of Biotech ETFs – ETF.com

Remember a few years ago when biotech ETFs were the hottest ticket in town? ETFs like the iShares NASDAQ Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) would rally 75% or more in a given year.

We saw bubblelike rallies in the early 2000s. We saw them again in the mid-2010s.

Then, in the last few years, this health care segment all but lost the wind on its sails.

Biggest Biotech ETF

IBB, the biggest biotech ETF, with $7.4 billion in assets under management, hasnt retested record highs in five years, grinding sideways for much of the time.

Chart courtesy of StockCharts.com

What Gives?

As a segment, biotech seemed reenergized in the last quarter of 2019. Strong fundamentals, attractive prices following a prolonged decline, and plenty of capital going around to fund these growthy names all pushed the segment higher late last year.

Many analysts kicked off 2020 by calling for biotech stocks to shine this year, continuing 2019s late upward momentum.

The goodand sometimes badnews for biotech ETF investors is that it doesnt take much to see biotech stock prices move sharply.

Virus Outbreak Puts Funds In Spotlight

This week, weve witnessed exactly thata sudden turnaroundwith the outbreak of the coronavirus in Asia pushing vaccine and other biotech names sharply higher.

Vaccine developer Novavax (NVAX) was up almost 13% in early trade Thursday after earlier-week gains; Moderna (MRNA) was up nearly 10%. These stocks have been rallying as news of the spreading outbreak hits the market.

Novavax is a micro-cap stock thats nowhere to be found in the biggest biotech ETFs. The only allocation to that stock in this segmentand a very small one at that, at 0.01%is in the iShares Evolved U.S. Innovative Healthcare ETF (IEIH).

IEIH is part of iShares Evolved lineup of funds that relies on artificial intelligence to define sectors, and its not truly a biotech fund. With 233 stocks, IEIH offers exposure to pharmaceuticals and biotechnology companies such as Johnson & Johnson, Merck, Pfizer and Bristol-Myers.

(Use ourstock finder toolto find an ETFs allocation to a certain stock.)

Accessing Moderna is a little easier. The stock can be found in several biotech ETFs, including IBB and XBI (between 1-1.5%).

But the biggest allocation to this stock is in much smaller funds that have been gathering traction due to their strong focus on genetics and immunotherapy.

Smaller Genetics-Focused ETFs Standing Out

Among the funds to note here is the Loncar Cancer Immunotherapy ETF (CNCR), which has Moderna among its top five holdings, at 4.5% of the portfolio.

CNCR is a portfolio of companies that manufacture cancer immunotherapy drugs or that are in clinical trials for these drugs in the U.S. and in Europe. The mix is equal-weighted, offering more exposure to some smaller names in this segment.

The iShares Genomics Immunology and Healthcare ETF (IDNA) is another ETF that has Moderna, at about 4.2% allocation. IDNA invests in companies involved in genomics, immunology and bioengineering across the globe. Stocks in this portfolio are scored based on revenue generated by these industries, looking for companies that would benefit the most from any innovation in these areas. IDNA launched last summer, and has $26.5 million in total assets.

Another small ETF that could emerge as a winner on the heels of this China-centered virus outbreak is a fund that focuses on Chinas biopharma segment, the Loncar China BioPharma ETF (CHNA). The fund invests in pharmaceutical and biotech companies, drug manufacturers and service providers, focusing on the biggest innovators in the space.

Its a tiny ETF, with under $12 million in assets, but, its also a young fund, having come to market in 2018.

Standout Favorite

One fund that has been emerging as a star in this segment, and becoming a favorite in this space, is the ARK Genomic Revolution ETF (ARKG).

ARKG is an actively managed fund that targets companies involved in the genomics industry. These are mostly small companiesthe average market cap of the portfolio is $20 billionand the fund relies on ARKs expertise to get in and out of positions as the market turns. Biotech represents about 75% of the funds segment breakdown, with names like Illumina, CRISPR Therapies and Invitae leading allocation.

ARKG is up 82.2% since its debut about five years ago, and currently sits near all-time highs. The fund has amassed more than $505 million in total assets under management along the way.

Whats Ahead?

At the end of day, it remains to be seen what happens next in biotech.

The question has lingered as to what drove the segment to have such lackluster performance in the past few years. This is a segment that sits on the edge of technological and scientific innovation, so has the poor performance (up until recently) been a reflection of a lack of new breakthroughs? Maybe.

And if so, it could be that 2020 changes that narrative as the market awaits what could potentially be the first Alzheimers drug to gain approval, according to reports.

It could also be that the recent track record on earnings and IPOs for this segment is mixed at bestthere have been success stories, but plenty of disappointment as well. Biotech companies are great at innovating, but they struggle to make a profit a lot of times.

In fact, most biotech ETFs have portfolios with negative price-to-earnings ratios, meaning these companies, which hold massive growth potential, often lose a lot of money along the way. Consider that XBI, for examplewhich holds more than 120 stockshas currently a weighted average P/E of -20, according to FactSet data. IBBs P/E is massively negative as well. CNCR and ARKG are in the same boat.

Perhaps its that biotech cant shake off the political overhang, with drug pricing at the forefront of political debates. And the ongoing opioid epidemic and subsequent lawsuits making for sensational headlines dont help.

Chances are, its a little bit of everything driving this segment up and down.

Contact Cinthia Murphy at [emailprotected]

See the original post:
The Love & Hate Of Biotech ETFs - ETF.com

Penn nanoparticles are less toxic to T cells engineered for cancer immunotherapy – Penn: Office of University Communications

New cancer immunotherapies involve extracting a patients T cells and genetically engineering them so they will recognize and attack tumors. This type of therapy is not without challenges, however. Engineering a patients T cells is laborious and expensive. And when successful, the alterations to the immune system immediately make patients very sick for a short period of time, with symptoms including fever, nausea and neurological effects.

Now, Penn researchers have demonstrated a new engineering technique that, because it is less toxic to the T cells, could enable a different mechanism for altering the way they recognize cancer, and could have fewer side effects for patients.

The technique involves ferrying messenger RNA (mRNA) across the T cells membrane via a lipid-based nanoparticle, rather than using a modified HIV virus to rewrite the cells DNA. Using the former approach would be preferable, as it only confers a temporary change to the patients immune system, but the current standard method for getting mRNA past the cell membrane can be too toxic to use on the limited number of T cells that can be extracted from a patient.

The researchers demonstrated their technique in a study published in the journalNano Letters. It was led by Michael Mitchell,Skirkanich Assistant Professor of Innovationof bioengineering in the School of Engineering and Applied Science, and Margaret Billingsley, a graduate student in his lab.

They collaborated with one of the pioneers of CAR T therapy: Carl June, the Richard W. Vague Professor in Immunotherapy and director of theCenter for Cellular Immunotherapiesin the Abramson Cancer Center and the director of the Parker Institute for Cancer Immunotherapy at the Perelman School of Medicine.

Read more at Penn Engineering.

Follow this link:
Penn nanoparticles are less toxic to T cells engineered for cancer immunotherapy - Penn: Office of University Communications

Global N-Hexanol Market Research Report 2019 by Manufacturers, Regions, Types and Applications – MENAFN.COM

(MENAFN - Nxtgen Reports) In this report, we provide assessment of market definition along with the identification of key players and an analysis of their ProductionRevenuePriceCost and Gross Margin their SWOT analysis for this market during the forecast period. Quantitative analysis of the industry from 2014 to 2025 by Region, Type, Application. Consumption assessment by regions. Industrial chain,upstream and downstream situation involved in this market.Geographically, global N-Hexanol market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players includingSasolGODAVARI BIOREFINERIESNANJING CHEMICAL MATERIAL CORPORATIONYancheng Hongtai BioengineeringChangzhou XiaQing ChemicalTRIVENI INTERCHEMNanjing Danpei Chemical

On the basis of product, we research the production, revenue, price, market share and growth rate, primarily split intotype 1type 2For the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of N-Hexanol for each application, includingPharmaceuticalSolventSurface active agentPlasticizerFatty alcohol productionProduction, consumption, revenue, market share and growth rate are the key targets for N-Hexanol from 2013 to 2024 (forecast) in these regionsChinaUSAEuropeJapanKoreaIndiaSoutheast AsiaSouth America

If you have any special requirements, please let us know and we will offer you the report as you want.

MENAFN2912201900709250ID1099485237

View original post here:
Global N-Hexanol Market Research Report 2019 by Manufacturers, Regions, Types and Applications - MENAFN.COM

Researchers have managed to bio-print a functional mini-liver in 90 days – FLWL News

Brazilian researchers claim to have bio-printed hepatic organoids. These are miniature versions of livers obtained from human blood cells. However, these mini-organs would be able to perform all the functions of a liver. This innovation gives new hope in terms of organ transplant.

A functional mini-liverIn their publication in the journal Biofabrication of November 27, 2019, researchers from the Human Genome and Stem Cell Institute in Sao Paulo (Brazil) indicated that they obtained a mini-liver through bio-printing. However, the latter would fulfill all the functions hoped for! These include the production of vital proteins, the storage of vitamins and the secretion of bile.

The researchers explained that they combined several bioengineering techniques. Indeed, the culture of pluripotent stem cells and cell reprogramming have been combined with 3D bio-printing. However, there is a difference compared to previous research. In fact, the cells were placed entirely in the bio-ink before being extruded. Previously, it was simply a matter of individual cells.

Relieve waiting for transplantNo less than 90 days were required, from collecting the patients blood to producing the tissue. First, the researchers reprogrammed the patients blood cells into induced pluripotent stem cells. Then, the differentiation of the cells made it possible to change them into liver cells. Finally, their spheroids may have been associated with bio-ink.

You should know that the project directors have bio-printed not one, but three mini-livers. Logically, the stem cells came from three different donors. The objective? Test the method then analyze the functionalities of the organs and the maintenance of cellular contact. As expected, the method worked much better than in the case of previous research incorporating individualized cells. The researchers said the technique could be replicated on a large scale.

Thus, this innovation could open up new hopes in terms of organ transplants. Indeed, the wait for an organ can be very long, which can be problematic. In China, tensions around the field of organ transplants have given rise to questionable research. In 2017, researchers said they wanted to clone pigs to recover their organs. The objective? To successfully transplant humans with these same organs and end the terrible waiting lists.

Lamia spent a couple of years interning at an organization that offered medical consultation before joining the editorial team at FLWL News. An enthusiastic fitness freak in the room, she offers the best amounts of insights and craft-based writing style to keep us up to date about the medicine industry, health and science.

Email:lamia@flwl.orgPhone: +1 512-845-8162

Follow this link:
Researchers have managed to bio-print a functional mini-liver in 90 days - FLWL News

Global Bio-decontamination Equipment Market 2019- Industry Innovative Growth with SWOT Analysis and Forecast-2026 – BulletintheNews

Global Bio-decontamination Equipment Market Forecast 2026 By Top Players, Applications, and its Types.

Global Bio-decontamination Equipment Market Research Report focuses on delevering the up-to-date and latest growth opportunities, 360-degree market overview, statistical data of Bio-decontamination Equipment industry. Bio-decontamination Equipment market size, share, revenue, growth rate, Consumption, company profile, and leading players are analyzed for the period 2019-2026.

The report highlights industry overview, growth trajectory, market dynamics, market share analyzed in detail this report. Bio-decontamination Equipment report numbers are driven by past, present and forecast market trends, development opportunities, market risks, and maturity analysis.

The report gives indepth analysis by segmenting the overall Bio-decontamination Equipment market based on type, application, end user and regions. Bio-decontamination Equipment type segment gives the in depth analysis of the global market share, production value and volume, price trends and growth rate exibited by each product type from 2014 to 2019.

Get Free Sample Report with Latest Bio-decontamination Equipment Industry Trends: https://www.reportspedia.com/report/chemicals-and-materials/global-bio-decontamination-equipment-market-research-report-2014-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/43947#request_sample

Market Segmented:

By Key Players Of the Bio-decontamination Equipment Market.

Fedegari GroupSTERIS Life ScienceBioquellWeike Biological LaboratoryHoworth Air TechnologyTailin BioEngineeringNoxilizerJCE BiotechnologyTOMI Environmental Solutions

By Type

Wall-mounted purification equipmentHanging purification equipmentCeiling-type purification equipmentFloor-standing purification equipment

By Application

ResidentialOfficemanufacturingHospital & HealthcareOthers

Bio-decontamination Equipment application fragment discusses the consumption ratio, market share, downstream buyers and growth rate from 2014 to 2019. Bio-decontamination Equipment fragment on regional level covers the market share, utilization, and production capacity, gross margin analysis for the regions namely North America, Europe, Asia-Pacific, Middle East & Africa, and South America

Get Discount on this Premium Report:https://www.reportspedia.com/report/chemicals-and-materials/global-bio-decontamination-equipment-market-research-report-2014-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/43947#inquiry_before_buying

It offers strategic market view by segmenting the overall market based on product type, application, end user and research regions. Key insights on global, regional and country level are presented in this report. The leading Bio-decontamination Equipment players are analyzed on the basis of recent developments, production value & volume, growth rate, and geographical presence. These Bio-decontamination Equipment industry players, regional geography, applications, and product type can be custom-made based on users requirement.

The valuable Bio-decontamination Equipment market insights like upstream raw material analysis, production process analysis, labor cost, raw material cost are covered in this report. Gross margin analysis, consumption ratio, Bio-decontamination Equipment import-export scenario, and SWOT analysis is presented in this report. The forecast Bio-decontamination Equipment industry insights pertaining to market value, volume, consumption will shape the future business growth.

Attractions Of The Report

Latest market dynamics, development trends and growth opportunities are presented along with industry barriers, developmental threats and risk factors

The forecast Bio-decontamination Equipment data will help in the feasibility analysis, market size estimation and development scope.

The report serves as a complete guide which micro monitors all vital Bio-decontamination Equipment segments.

A concise market view will provide ease of understanding.

Bio-decontamination Equipment Competitive market view will help the players in making a right move

Table Of Content:

1 Global Market Overview

1.1 Scope of Statistics

Scope of Products

Scope of Manufacturers

Scope of Application

Scope of Type

Scope of Regions/Countries

1.2 Global Market Size

2 Regional Market

Regional Production

Regional Demand

Regional Trade

3 Key Manufacturers Information

Company Information

Product & Services

Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)Recent Development

More

Browse Full Report with Facts and Figures of Bio-decontamination Equipment Market Report at:https://www.reportspedia.com/report/chemicals-and-materials/global-bio-decontamination-equipment-market-research-report-2014-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/43947#table_of_contents

See the original post:
Global Bio-decontamination Equipment Market 2019- Industry Innovative Growth with SWOT Analysis and Forecast-2026 - BulletintheNews

BETiC, SINE and IITB-AA hosts ‘start to scale up’ workshop for med-tech start-ups – India Education Diary

Mumbai: Biotechnology Industry Research Assistance Council (BIRAC) under the Ministry of Science and Technology, Government of India presented a curtain raiser to the Global Bio-India 2019 programme at Start to Scaleup workshop.

Society for Innovation and Entrepreneurship (SINE), at IIT Bombay organized a start-to-scale program for healthcare and Bio MedTech startups.

The workshop was supported by BETiC (Biomedical Engineering and Technology (Incubation) Center), WRCB (Wadhwani Research Centre for Bioengineering) and DSCE (Desai Sethi Centre for Entrepreneurship).

Over 50 attendees from across the nation showed up at the workshop. The event addressed vital issues in medtech and healthcare space.

The workshop comprehended sessions such as regulatory landscape & clinical trials, intellectual property rights, partnerships & commercial agreements, preparing for sales & marketing, and business models and fundraising. In addition, there was also a session on leveraging academic ecosystem which offers a strong value addition to early stage entrepreneurs.

Setting a tone at the event, Ms. Poyni Bhatt, CEO, SINE, Healthcare and MedTech startups face unique challenges in terms of long gestation period, need for clinical trials and regulatory compliances, and importance of various partnerships, and need for larger capital in very early stages of their development. The workshop was aimed at helping entrepreneurs understand and encourage discussions around all these aspects within themselves and with experts.

The event concluded with a startup journey by a healthcare service startup which affixed to the learning experience for amateur entrepreneurs.

Read the rest here:
BETiC, SINE and IITB-AA hosts 'start to scale up' workshop for med-tech start-ups - India Education Diary

Plastic: The many good uses of a vilified modern material – The Irish Times

Plastic: Cant Live With It, Cant Live Without It is a new exhibition at Dublins Science Gallery. It draws our attention to our complex relationship with this ubiquitous material. While a lot of focus of late has been on the environmental damage of single-use plastics particularly on bird and fish life the reality is that plastic is also used in a myriad of positive ways in industry and medicine.

Plastic is so vilified now, but people underestimate the reliance we have on it for healthcare. Modern healthcare would be impossible without the many plastic-based medical products we take for granted, such as pills coated with plastic to control the release of the drug once ingested, says Prof Michael Monaghan, assistant professor of biomedical engineering at Trinity College Dublin.

Prof Monaghan, curatorial adviser to the Science Gallery exhibition, has helped create an exhibit on open-source plastic medical devices developed through 3D printing. He believes plastic is superior to many other materials, because its cheap and because each piece can be sterilised.

Students in the masters in bioengineering at Trinity design devices that are needed in healthcare (eg a diagnostic tool for malaria, or a box for the safe disposal of needles), and we upload their codes to our website so that anyone around the world can download them. 3D printing in a smart connected world allows us to 3D print anything we want in plastic, he explains.

The biohybrid robotic respiratory simulator is another exhibit made from flexible plastic and electrics. It, too, highlights the role of plastic in healthcare. Markus Horvath from Massachusetts Institute of Technology says this particular model is used for teaching students as well as for inventing new medical devices.

The impact of plastics in a destructive way is well documented but they are also used in medical technology to save lives, says Horvath. Another exhibit is of 3D-printed plastic human organs, used by students to practise surgery.

Several exhibits, however, focus on the overconsumption of plastic. One asks whether people would wear a self-tracking device that would capture their consumption of plastic and shame them or celebrate their results. Another has playfully constructed an environmental checkpoint to protect natural resources that people with plastics (even fleece jackets, chewing gum, and pens) would not be able to pass.

And an exhibit entitled The Peoples Plastic is a shelving unit filled with plastic bottles with warning labels highlighting the damage single-use plastics do to the environment. Mindy OBrien from the environmental NGO Voice says: Its a great idea, but I think such labels should also have information on the plastics used in packaging, because some chemicals leach into food.

OBrien, who works on initiatives to reduce plastic pollution, remains concerned about where much of single-use plastic ends up. I think deposit-refund schemes are a good way of collecting plastic bottles for recycling but Id really like to see deposit-refund schemes for reuse of plastic bottles. Ultimately, we need a paradigm shift where we look at the product (eg vending machines for water) rather than the packaging.

A ban on single-use plastic items including cotton buds, polystyrene cups, plastic cutlery and straws is due to be imposed from 2021. Other EU legislation will require 50 per cent of plastic waste to be recycled by 2025 and all plastic to be easily recyclable by 2030. With these changes in mind, eco-designers are turning their attention to alternatives to petrochemical-based plastics and new uses for recycled plastic.

An exhibit entitled An B Bheannaithe (The Blessed Cow) shows how a byproduct of whey protein production can be used to create a compostable bioplastic. Visitors to the exhibition can also try making this bioplastic at workshops.

A tricycle made from prefabricated sheets of recycled plastic shows a potential new use for what might be a glut of recyclable plastics if and when the EU Single-Use Plastics Directive is enforced. An original 1968 Italian-designed Monobloc chair is also on show as an example of an easy-to-make, durable, low-cost stackable chair made from recycled plastic.

Abigail Murphy fromthe Environmental Protection Agency hopes the exhibition will raise awareness of plastic as an innovative material and not just something that is overconsumed. Plastics are priority areas for [our waste prevention office], and we offer innovation grants for the circular economy [where materials are brought back into circulation rather than disposed of].

Ruth Doyle, another curatorial adviser, who has a PhD in sustainable lifestyles and runs @missionzerowaste on Instagram, hopes the exhibition will promote conversations about overconsumption in general of which the plastics problem is a symptom.

There is a need for more ethical and conscious consumption, and this can be a gateway to awareness of other environmental issues. There are substitutes for a lot of plastic items some of which are smart, modern alternatives such as reusable nappies. The problem is they are still niche products, so they need to be more readily available, says Doyle.

And has the Science Gallery changed any of its own practices? We used a sustainable events company when mounting the exhibition, which will tour to five locations around Ireland. This company planned the reuse of materials 30 per cent of which is plastic for schools, festivals and community centres once the exhibition is over, explains Aisling Murray, exhibitions manager at the Science Gallery.

The gallery has also recently added a composting bin alongside its general waste and recyclables bins, so that customers can dispose of compostable cups correctly. Next week, a hydration station will be installed. The Science Gallery cafe has also switched from plastic bottles to cans for all drinks sold on site.

Plastic: Cant Live With It, Cant Live Without It will run in the Dublin Science Gallery until February 9th, 2020, after which it will tour to Drogheda, Letterkenny, Wexford, Limerick and Galway. dublin.sciencegallery.com/plastic

Read the original:
Plastic: The many good uses of a vilified modern material - The Irish Times

Eun Ji Chung Named as IEEE New Innovator and BMES Rising Star – USC Viterbi School of Engineering

Dr. Karl Jacob Jr. and Karl Jacob III Early-Career Chair Eun Ji Chung. Photo courtesy of Viterbi Staff.

Eun Ji Chung, USC Viterbis Dr. Karl Jacob Jr. and Karl Jacob III Early-Career Chair and Assistant Professor of Biomedical Engineering, Chemical Engineering and Materials Science, has recently been honored by the Institute of Electrical and Electronics Engineers (IEEE) and the Biomedical Engineering Society (BMES) for her research in nanomedicine and bioengineering.

The IEEE has selected Chung as a NANOMED New Innovator, with the award to be presented at the IEEE International Conference on Nano/Molecular Medicine and Engineering in Gwangju, Korea on 21 24 November. The latest honor recognizes Chungs eminent research activities in the field of nanomedicine and molecular engineering as well as her continuous contribution to the IEEE-NANOMED community.

Meanwhile the BMES will honor Chung with the 2020 Rising Star Junior Faculty Award, to be presented at the BMES Cell and Molecular Bioengineering conference on January 2 6 in Puerto Rico. Chung will be recognized at the conference gala, and will be invited to present at the event. The BMES describes the Rising Star Award as a leading form of recognition of outstanding research in the field of cell and molecular bioengineering.

Chung and her research groupinvestigate molecular design, nanomedicine and tissue engineering to generate biomaterial strategies for clinical applications. A key focus of Chungs labs research involves the design and application of self-assembling, peptide nanoparticles for targeted cardiovascular and cancer treatments, as well as for the treatment of kidney disease.

A faculty member of theUSC Michelson Center for Convergent Bioscience, Chung received her B.A. in Molecular Biology with honors from Scripps College, Claremont, California, and her Ph.D. from the Interdisciplinary Biological Sciences Program and the Department of Biomedical Engineering from Northwestern University.

She was recently named 2019 Orange County Engineering Council Outstanding Young Engineer and a Journal of Materials Chemistry B Emerging Investigator for 2019.

Last year, Chung was awarded the NIH New Innovator Award to develop a new approach to a type of kidney disease, known as autosomal dominant polycystic kidney disease, the most commonly inherited kidney disorder.

Chung is a recipient of the SQI-Baxter Early Career Award, the American Heart Association Postdoctoral Fellowship, the Postdoctoral Research Grant from the Chicago Biomedical Consortium, and the K99/R00 Pathway to Independence Award from the NIH. She is a member of the Society for Biomaterials, the BMES, and the American Institute for Chemical Engineers.

Read more:
Eun Ji Chung Named as IEEE New Innovator and BMES Rising Star - USC Viterbi School of Engineering

Bioengineering | College of Engineering

The Bioengineering Programprovides a seriesof professional studies grounded in engineering fundamentals and arts and sciences and augmented by the development of interpersonal skills, experiential learning, and an appreciation of lifelong learning. Graduates are prepared to apply their knowledge to societys needs and help shape the future.

Training in bioengineering prepares graduatesto work invarious fields, such as:

Our graduates can expect to work in places like:

The three different tracks in thisprogram will prepare graduates for a variety of careers. Among them are:

* This elective requirement includes 3 credits of Foreign Language/ Diversity, 6 credits of Humanities/ Social Science/ Theology, and 12 credits of Bioengineering Technical Electives.

* Twelve credits of bioengineering courses (or approved mechanical engineering or electrical engineering courses) are to be selected to provide areas of individual study emphasis. Up to three credits may be substituted for students participating in undergraduate research within the College of Engineering.

Click herefor mechanical/ bioengineering elective information.

Computer Specifications: When looking for a computer to use for engineering classes, please refer to this PDF for the specifications.

* The elective requirement includes 3 credits of Foreign Language/Diversity, 6 credits of Humanities/Social Science/Theology, and 4 credits of Bioengineering Technical Electives.

* Four credits of bioengineering courses (or approved mechanical engineering or electrical engineering courses) are to be selected to provide areas of individual study emphasis. Up to three credits may be substituted for students participating in undergraduate research within the College of Engineering.

Click herefor mechanical/ bioengineering elective information.

Computer Specifications: When looking for a computer to use for engineering classes, please refer to this PDF for the specifications.

*The elective requirement includes 3 credits of Foreign Language/Diversity,3 credits of Humanities/Social Science/Theology, and3 credits of Bioengineering Technical Electives.

* Three credits of bioengineering courses (or approved mechanical engineering or electrical engineering courses) are to be selected to provide areas of individual study emphasis. Up to three credits may be substituted for students participating in undergraduate research within the College of Engineering.

* Note: PSY 110 General Psychology (3 credits) should also be taken to prepare for the MCAT.

Click herefor mechanical/ bioengineering elective information.

Computer Specifications: When looking for a computer to use for engineering classes, please refer to this PDF for the specifications.

Read more here:
Bioengineering | College of Engineering

ASU biomedical engineer spotlighted as emerging international leader – Arizona State University

ASU graduate and undergraduate students are getting valuable research experience in Associate Professor Sarah Stabenfeldts lab. Her work on developing new and improved approaches to treating neural injury has been highlighted by a leading international science organization. Photo by Jessica Hochreiter/ASU Download Full Image

More than 50 researchers from around the world are featured in those issues of the Journal of Materials Chemistry B and Biomaterials Science.

Stabenfeldt, an associate professor of biomedical engineering in the Ira A. Fulton Schools of Engineering at Arizona State University, is the only one among them with research papers published in the special editions of both journals.

Her work focuses on developing a variety of novel approaches to treat neural injury, primarily traumatic brain injury.

The recent publications in the Royal Society of Chemistry journals describe research by Stabenfeldt and her team of biomedical engineering graduate and undergraduate students to develop and evaluate biodegradable particles used to release small doses of therapeutic proteins to the brain over time. Recent doctoral graduate Dipankar Dutta and current doctoral student Kassondra Hickey played key roles in the projects.

Such therapeutic methods, along with the techniques and tools used to implement them, hold out hope for better ways to diagnose and treat traumatic brain injury and other neurological injuries and traumas.

Peers in the field envision her research helping to make major advances in unveiling the biological basis of traumatic brain injury, which could save the lives of thousands of patients, says Mehdi Nikkhah, a fellow Fulton Schools biomedical engineering faculty member.

Her research approach is grounded in a comprehensive understanding of the mechanisms of disease progression, and her designs for targeted therapeutics utilize some of the most cutting-edge bioengineering-based strategies, Nikkhah said. Overall, she is addressing some of our biggest healthcare challenges.

Stabenfeldts research aimed at improving the diagnosis and treatment of traumatic brain injury could saves the lives of thousands of patients, says fellow biomedical engineer Mehdi Nikkhah. Photo by Cheman Cuan/ASU

Stabenfeldt earned her doctoral degree in bioengineering from the Georgia Institute of Technology and then conducted research as a National Institutes of Health post-doctoral fellow at Georgia Tech and Emory University.

Since coming to ASU in 2011, she has co-authored more than 20 peer-reviewed articles for research publications including the particularly prominent journals Nature Materials and Biomaterials along with three book chapters.

Her work has earned support through an Arizona Biomedical Research Consortium Early Stage Investigator Award, the NIH Directors New Innovator Award and a National Science Foundation CAREER Award.

Each of these prestigious awards are given to young faculty members who are seen as future research and education leaders in their fields.

Very few junior faculty members have received more than one of these awards. This achievement undoubtedly places her among those at the forefront of biomedical engineering, Nikkhah said.

All of this recognition indicates the significant impact of Sarahs work to develop next-generation diagnostics and therapeutics for neurological-related disorders such as traumatic brain injury, said colleague David Brafman, an assistant professor of biomedical engineering in the Fulton Schools, adding that her impact extends beyond the work she is doing in her lab.

As one of the first female tenured faculty members in our program, Sarah also recognizes the importance of mentoring the next generation, Brafman said. Her service as the faculty advisor for the undergraduate Biomedical Engineering Society is one of many ways she has become a positive role model for future biomedical scientists and engineers.

The Royal Society of Chemistry, based in the United Kingdom, has more than 54,000 members worldwide.

The organization publishes more than 40 peer-reviewed research journals and many books, as well as online databases and literature updating services, covering the core chemical sciences and related fields such as biology, biophysics, energy and environment, engineering, materials, medicine and physics.

Stabenfeldt says being selected to publish in two of the societys journals highlighting emerging research leaders should boost opportunities for additional support for her projects and possibly generate invitations to present her work at medical science and bioengineering conferences.

Read abstracts of her research papers in the Journal of Materials Chemistry B and Biomaterials Science. At the end of each abstract are links to content from the recent special issues of the journals.

Continued here:
ASU biomedical engineer spotlighted as emerging international leader - Arizona State University

Ecovative lays off 18 as it shifts gears toward bioengineering – Albany Times Union

Machine operators move protective packaging material, that's made from mushrooms, from molds to a cart on Tuesday, Feb. 16, 2016, at Ecovative Design in Troy, N.Y. From left are Aaron Ford, Lance Tucker and Aldwin Berry. (Cindy Schultz / Times Union) less Machine operators move protective packaging material, that's made from mushrooms, from molds to a cart on Tuesday, Feb. 16, 2016, at Ecovative Design in Troy, N.Y. From left are Aaron Ford, Lance Tucker and ... more Photo: Cindy Schultz Mayor Patrick Madden, center, holds protective packaging while production manager Katie Malysa, right, explains it's made from mushrooms on Tuesday, Feb. 16, 2016, at Ecovative Design in Troy, N.Y. At left is Andy Ross of Ross Valve. (Cindy Schultz / Times Union) less Mayor Patrick Madden, center, holds protective packaging while production manager Katie Malysa, right, explains it's made from mushrooms on Tuesday, Feb. 16, 2016, at Ecovative Design in Troy, N.Y. At left is ... more Photo: Cindy Schultz

Machine operator Lance Tucker, right, carries protective packaging material, that's made from mushrooms, on Tuesday, Feb. 16, 2016, at Ecovative Design in Troy, N.Y. (Cindy Schultz / Times Union)

Machine operator Lance Tucker, right, carries protective packaging material, that's made from mushrooms, on Tuesday, Feb. 16, 2016, at Ecovative Design in Troy, N.Y. (Cindy Schultz / Times Union)

Ecovative lays off 18 as it shifts gears toward bioengineering

Ecovative Design, the Green Island startup that makes building and packaging materials out of biodegradable mushroom material, is laying off 18 people, between 20 to 30 percent of its total staff.

The job cuts are the first major layoffs that Ecovative CEO Eben Bayer has had to do since he co-founded the company about 10 years ago while a student at Rensselaer Polytechnic Institute in Troy.

Ecovative, which recently won a $9.1 million grant from the Defense Advanced Research Projects Agency, or DARPA, is now headquartered in Green Island in 32,000 square feet of space and has a second manufacturing facility in Troy with 20,000 square feet of space.

The layoffs are associated with the cessation of two new product projects that have ended for different reasons. In one case, a commercial partner had decided not to fund a Phase II of the program.

"The projects that these folks were working on went away," Bayer told the Times Union. "We're not shutting down. We're not going away. We're not ceasing production. We're continuing to do manufacturing."

Still, Bayer said he had to let some really good employees go, and it was not easy for him or others in management to make that decision. The company employed in the neighborhood of 70 people before the layoffs occurred.

However, he said the company has to remain sustainable in the long run, one of the reasons why the company did not decide to try and subsidize the jobs without corresponding revenue.

"It's sad," Bayer said. "This was so hard."

Bayer added that he believes the teams that were laid off will become assets at other companies quickly.

"Those impacted are some of the smartest, hardworking and talented individuals I have worked with," Bayer said. "I know that their skills will be in high demand in the Capital Region."

Laid-off workers received compensation and health care packages that depended on their length of service.

The layoffs come, however, as Ecovative, a privately held company that does not reveal financial data to the public, is shifting gears in a way that may end up leading to many more hires.

One of the new product programs could also be re-launched as a spin-off company, but Bayer said it was too early to sustain it now on its own. He said both product programs were secret and the company did not publicize what they were working on.

Bayer said the company has exhausted what it can do with using native mycelium, the fungus "filaments" that grow into mushrooms, to bind together other biodegradable materials into molds.

Instead, the company has started experimenting with bioengineering mycelium to create new properties in self-growing building materials for instance mycelium that can be certain colors or have insect resistant properties. The DARPA grant is being used to create bioengineered materials that will grow temporary shelters in place.

The ideas of bioengineering these new self-growing materials are limitless, and have a much larger market potential than the company's current product line of MycoBoard and MycoFoam.

"For me, that's the next frontier," Bayer said. "I'm really excited about it."

The company is currently hiring a molecular biology technician as part of this new research and development push.

"This role will perform molecular biology techniques, strain preservation and maintenance, species cultivation, substrate preparation and mixing, maintain lab inventory, assist in scale up, prepare materials for experimentation, and perform data collection," the job posting states.

Go here to read the rest:
Ecovative lays off 18 as it shifts gears toward bioengineering - Albany Times Union

TSG: Two vacant Parliament seats filled after committee approval – Temple News

Parliaments steering committee approved representatives for the College of Engineering and the School of Theater, Film and Media Arts, which went unfilled after the Spring TSG elections.

by Amanda Lien 03 August 2017

Junior bioengineering major Neil Chada (left) and sophomore musical theater major Doreen Nguyen were approved to fill vacant seats in Temple Student Government's Parliament. COURTESY NEIL CHADA AND DOREEN NGUYEN

Temple Student Governments steering committee voted Monday to approve candidates for two vacant Parliament seats.

Parliamentarian Jacob Kurtz appointed junior bioengineering major Neil Chada for the College of Engineering seat and sophomore musical theater major Doreen Nguyen for the School of Theater, Film and Media Arts seat in late June.

Chada and Nguyen sent their resumes and statements of interest to members of the steering committee, who began questioning them via email in early July. Questioning ended in mid-July, but a vote was not taken until the end of the month.

According to the TSG Constitution, both candidates need to be approved by the steering committee in a simple majority vote. Both candidates were approved 7-1.

The steering committee, which is made up of the Speaker and the committee heads, is responsible for setting the Parliament agenda and approving new appointments to Parliament. A new steering committee has not been established by the current Parliament but members of the former steering committee retain emeritus membership status, which allows them to vote on new appointments to Parliament until a new steering committee can be established.

The current steering committee is made up of the former Speaker and the seven former committee chairs.

Chada said that his goal is to get engineering students talking about TSG as a place to bring comments and concerns since he feels like TSG was lacking representation from the College of Engineering last year.

A lot of times, the people in engineering get carried away with what theyre doing and everyone feels like no one has an avenue where they can project their voices, he said. My primary focus is to streamline that and make it accessible to everyone.

Outreach to the academic advising office and faculty are among his top priorities as a representative, he added.

Nguyen said she hopes to ensure that her school has more of a voice in TSG by talking to large classes and using her positions as a peer adviser and resident assistant to hear different concerns.

A lot of people [in TFMA] dont feel as represented on TSG, she said. I want to be that person they can go to with concerns that I can bring up to the entire student government.

After this vote, there are still three vacant Parliament seats: Boyer College of Music and Dance, Transfer Students and Graduate/Fifth Year Plus. The primary focus within Parliament is training the existing Parliament representatives, Kurtz said, adding that once that is completed he will work with the Elections Commissioner to try to fill the seats.

Two freshman class representatives, the RHA representative and the Greek life representative will be elected at the beginning of the fall semester.

Amanda Lien can be reached at amanda.lien@temple.edu.

Excerpt from:
TSG: Two vacant Parliament seats filled after committee approval - Temple News

Clemson prof gets $6M for research to lower price of drugs used to treat breast cancer, MS – Greenville Journal

Sarah Harcum, professor of bioengineering, works in her lab at Clemson University. Photo Credit: Clemson University.

Clemson University professor Sarah Harcum has been awarded a $6 million grant from the National Science Foundation to study ways to lower the cost of drugs for illnesses such as Crohns disease, breast cancer, severe anemia, and multiple sclerosis.

Harcum and several other researchers plan to research better ways of engineering Chinese hamster ovary cells, which the drug industry uses to produce half of allbiopharmaceuticals.

According to Harcum, a bioengineering professor, Chinese hamster ovary cells arehighly adaptable, bear no human viruses, and are capable of high-level production. But the hamster cells have one flaw: Genetic drift, a series of mutations that ultimately hinders drug production for manufacturers and increases prices for patients.

Genetic drift begins at cell development, according to Harcum.

A line of ovarian cells ideally develops with a uniform genetic composition, which is necessary for the efficient production of all biopharmaceuticals. Unfortunately,the composition drifts as cells reproduce, and they become less effective at creating drugs.

As a result, production becomes more expensive as they require more monitoring, control, and analysis throughout the manufacturing process.Some biopharmaceuticals under current production conditions can cost patients thousands of dollars per treatment, according to Harcum.

Harcum said she became aware of genetic drift in hamster cells during her time as a staff fellow at the Federal Drug Administration in the 1990s. Shes since studied how to disable the underlying mechanism responsible for the genetic drift, using a set of hamster cells that were originally cultured in 1957.

Now, using the grant, Harcum is teaming up with researchers from the University of Delaware, Tulane University, and Delaware State University to find a solution.Harcum said the study is expected to improve the manufacturing process for biopharmaceuticals, creating more affordable prices for patients.

We expect by the end of the study we will have identified some genes that cause the instability, said Harcum. With success, the Chinese hamster ovary cell line will stay more stable during the manufacturing.We hope to get that drift to be reduced; thats the ultimate goal.

Harcum plans to use the grant money to install an industry-grade bioreactor in her lab at the Biosystems Research Complex on the main Clemson University campus.

As part of the project, Harcum and her colleagues plan to use part of the grant money to recruit female and minority research assistants to promote diversity. They also plan to recruit three-tenure track faculty members to promote the field of bioengineering, which has faced a shortage of masters and doctoral-level researchers in recent years.

Medical patients could be less likely to reject artificial hips, knees and other medical implants.

Amor Ogale received $2 million in collaboration with the Center for Composite Materials at University

The operating system thats under development, known as S2OS, could make data stored and transmitted

Clemson researchers have been awarded five high-profile research grants

Read the original post:
Clemson prof gets $6M for research to lower price of drugs used to treat breast cancer, MS - Greenville Journal

Director of Bioengineering Institute receives international accolade … – Voxy

The Director of the University of Aucklands Bioengineering Institute (ABI) has been awarded an honorary doctorate from the University of Sheffield, in the United Kingdom.

Distinguished Professor Peter Hunter, who is renowned for his work in the fields of in silico medicine and computational physiology, will receive the doctorate in engineering on 18 July 2017.

"This award means a lot to me," says Professor Hunter. "The Insigneo Institute led by Professor Marco Viceconti at the University of Sheffield is the preeminent bioengineering institute in Europe."

Professor Hunter completed his engineering degrees at the University of Auckland before undertaking his DPhil (PhD) in Physiology at the University of Oxford. Since then he has pioneered the use of computational methods for understanding the integrated physiological function of the body in terms of the structure and function of tissues, cells and proteins.

Alongside his role as Director of ABI and Professor of Engineering Science at the University of Auckland, Professor Hunter is also Director of Computational Physiology at Oxford University, and Director of the Medical Technologies Centre of Research Excellence (MedTech CoRE) hosted by the University of Auckland. He was appointed to the NZ Order of Merit in 2010 and in 2009 received an honorary doctorate from the University of Nottingham.

Read more here:
Director of Bioengineering Institute receives international accolade ... - Voxy

Bioengineering – University of California, San Diego

[ graduate program | courses | faculty ]

STUDENT AFFAIRS 141 Powell-Focht Bioengineering Hall Warren College http://www.be.ucsd.edu

All courses, faculty listings, and curricular and degree requirements described herein are subject to change or deletion without notice. Updates may be found on the Academic Senate website: http://senate.ucsd.edu/catalog-copy/approved-updates/.

Bioengineering is an interdisciplinary major in which the principles and tools of traditional engineering fields, such as mechanical, materials, electrical, and chemical engineering, are applied to biomedical and biological problems. Engineering plays an increasingly important role in medicine in projects that range from basic research in physiology to advances in biotechnology and the improvement of health-care delivery. By its very nature, bioengineering is broad and requires a foundation in the engineering sciences as well as in physiology and other biological sciences.

The overall mission of the Department of Bioengineering is to improve health and quality of life by applying engineering principles to scientific discovery and technology innovation and to train future leaders in bioengineering through inspiring education and dedicated mentorship.

The educational objectives of the bioengineering program at UC San Diego are to produce graduates with a modern bioengineering education who will

At the undergraduate level, the department offers several four-year engineering majors, including a newly developed BS in Bioengineering: BioSystems. This major focuses on the interaction and integration of components in complex biological and engineering assemblages, and how the function and interactions of these components affect overall performance. The major draws on foundations of classical electrical and systems engineering, with biological applications at levels of the molecular and cellular to the physiological and whole organism, and provides an alternative to other bioengineering majors that emphasize mechanical, chemical, and computational approaches. The major prepares students for careers in the bioengineering industry, in research and development, and for further education in graduate, medical, and business schools.

One major leads to a BS in Bioengineering. This major prepares students for careers in the biomedical device industry and for further education in graduate school. Students completing the BS in Bioengineering have a broad preparation in traditional topics in engineering, allowing for a variety of career pathways. This program addresses the bioengineering topics of biomechanics, biotransport, bioinstrumentation, bioelectricity, biosystems, and biomaterials, and the complementary fields of systems and integrative physiology. Education in these areas allows application of bioengineering and other scientific principles to benefit human health by advancing methods for effective diagnosis and treatment of disease, e.g., through development of medical devices and technologies.

The department also offers a BS in Bioengineering: Biotechnology. This major prepares students for careers in the biotechnology industry and for further education in graduate school. The curriculum has a strong engineering foundation with emphasis on biochemical process applications. This program addresses the bioengineering topics of biochemistry, metabolism, kinetics, biotransport, biosystems, bioreactors, bioseparations, tissue engineering, and the complementary fields of cellular physiology. Education in these areas allows application of bioengineering and physicochemical principles to cellular and molecular biology, with the applications that benefit human health.

The department also offers a major leading to a BS in Bioengineering: Bioinformatics. Bioinformatics is the study of the structure and flow of information (genetic, metabolic, and regulatory) in living systems. The bioinformatics major emphasizes computation and model-based approaches to assembling, integrating, and interpreting biological information. This major has been developed by the Departments of Bioengineering, Chemistry and Biochemistry, Computer Science and Engineering, and the Division of Biological Sciences, and students may apply through any of these departments or the division. The major prepares students for careers in the pharmaceutical, biotechnology, and biomedical software industries, and for further studies in graduate or medical school.

The programs and curricula of the Department of Bioengineering emphasize education in the fundamentals of engineering sciences that form the common basis of all engineering subspecialties. Education with this emphasis is intended to provide students with an interdisciplinary engineering foundation for a career in which engineering practice may expand rapidly. In addition, elements of bioengineering design are incorporated at every level in the curricula. This is accomplished by integration of laboratory experimentation, computer applications, and exposure to real bioengineering problems throughout the program. In the Bioengineering, Bioengineering: Biotechnology, and Bioengineering: BioSystems majors, students also work in teams on a senior design project to design a solution to a multidisciplinary bioengineering problem suggested by professionals in bioengineering industry, academia, or medicine.

The Engineering Accreditation Commission of the Accreditation Board for Engineering and Technology (EAC/ABET) is an organization with a mission of serving the public through promotion and advancement of education in fields including engineering, and ABETs strategic plans include accreditation of educational programs and promotion of quality and innovation in education http://www.abet.org. At UC San Diego, Bioengineering, Bioengineering: Biotechnology, and Bioengineering: BioSystems have a relatively heavy emphasis on engineering, whereas Bioengineering: Bioinformatics has a relatively heavy emphasis on biological, chemical, and physical sciences. The Bioengineering and Bioengineering: Biotechnology programs are accredited by EAC/ABET, and ABET accreditation will be sought for the Bioengineering: BioSystems major. The Bioengineering: Bioinformatics program is not accredited by a Commission of ABET.

At the graduate level, specialized curricula lead to the MS, MEng (Master of Engineering), and PhD, as well as an integrated BS/MS. The department also offers a PhD in Bioinformatics. It is intended for students who have an interdisciplinary persuasion to work across computers, biology, medicine, and engineering. For further information on the degree, please e-mail bioinfo@ucsd.edu or go online to http://www.bioinformatics.ucsd.edu. The MEng is a terminal professional degree whereas the MS and PhD are research programs. (See section on masters degree programs.) The graduate programs are characterized by strong interdisciplinary relationships with the other engineering departments and Departments of Physics, Mathematics, Biology, Chemistry and Biochemistry, Medicine, and others, as well as with campus organizations such as the Institute of Engineering in Medicine, Institute for Mechanics and Materials, and the School of Medicine.

Specific course requirements for each of the majors are outlined in tables below. In addition to the required technical courses specifically indicated, a suggested scheduling of humanities and social science courses (HSS) is included in the curricula for students to use to meet college general-education requirements. To graduate, students must maintain an overall GPA of at least 2.0, and obtain at least a C grade in each course required for the major. All courses required for the major must be taken for a letter grade.

Deviations from the required programs of study must be approved by the Undergraduate Studies Committee prior to students taking alternative courses. In addition, students must obtain departmental approval of technical elective (TE) course selections prior to students taking the course. In the ABET-accredited programs, TE courses are restricted to those that meet ABET standards. Courses such as BENG 197 and 198 are encouraged, but do not count as upper-division technical electives. BENG 195, 196, and 199 can be used as technical electives under certain conditions. Policy information may be obtained from the Student Affairs Office.

Students with accelerated academic preparation at admission to the university may vary the scheduling of lower-division courses such as mathematics, physics, and chemistry, but must first consult the department. Most lower-division courses are offered more than once each year to permit students some flexibility in their program scheduling. However, most upper-division bioengineering courses are taught only once each year.

Deviations in the scheduling of upper-division bioengineering courses are strongly discouraged, as such changes usually lead to a delay in graduation.

The curricula shown in the tables below are consistent with the current scheduling of classes.

Minors are not offered in the Department of Bioengineering, and double major options are restricted. Students interested in double majors should consult the Student Affairs Office as early as possible.

For graduation, each student must satisfy general-education course requirements determined by the students college, as well as the major requirements determined by the department. The six colleges at UC San Diego require different general-education courses, and the number of such courses differs from one college to another. Each student should choose his or her college carefully, considering the special nature of the curriculum and the breadth of general education.

The bioengineering programs allow for humanities and social science (HSS) courses so that students can fulfill their college requirements. In the bioengineering ABET-accredited programs, students must develop a program that includes a total of at least forty units in the arts, humanities, and social sciences, not including subjects such as accounting, industrial management, finance, or personnel administration. It should be noted, however, that some colleges require more than the ten HSS courses indicated in the Bioengineering, Bioengineering: Biotechnology, Bioengineering: Bioinformatics, and Bioengineering: BioSystems curriculum tables. Accordingly, students in these colleges may take longer to graduate than the four years indicated in the schedule. Students must consult with their colleges to determine which HSS courses to take.

(ABET-Accredited Program)

1Chem 7L may be taken in any quarter within the first two years after completion of Chem 6B.

2BENG 1 may be taken in sophomore year.

3Ten HSS courses are listed here; individual college requirements may be higher.

4Recommended course, not required.

5Design elective (DE) courses must be selected from a two-quarter sequence, BENG 119AB, 126AB, 127AB, 128AB, 129AB, 139AB, 147AB, 148AB, 149AB, 169AB, 179AB.

6Math 20F and MAE 140 may be taken concurrently.

7Technical elective (TE) courses must be selected from a departmental approved list. Consult the Student Affairs Office.

(ABET-Accredited Program)

1Chem 7L may be taken concurrently with Chem 6C or in any quarter within the first two years after completion of Chem 6B.

2BENG 1 may be taken in sophomore year.

3Continuing students who have completed MAE 9 or 10 are NOT REQUIRED to take MAE 8 and future Transfer students who have completed a course equivalent to MAE 9 or 10 are exempted from completing MAE 8 until fall 2013.

4Ten HSS courses are listed here; individual college requirements may be higher.

5Recommended course, not required.

6Design elective (DE) courses must be selected from a two-quarter sequence, BENG 119AB, 126AB, 127AB, 128AB, 129AB, 139AB, 147AB, 148AB, 149AB, 169AB, 179AB.

7Technical elective (TE) courses must be selected from a departmental approved list. Consult the Student Affairs Office.

(ABET Accreditation to be sought.)

1Ten HSS courses are listed here; individual college requirements may be higher.

2Technical elective (TE) courses must be selected from a departmental approved list. Consult the Student Affairs Office.

3Design elective (DE) courses must be selected from a two-quarter sequence, BENG 119AB, 126AB, 127AB, 128AB, 129AB, 139AB, 147AB, 148AB, 149AB, 169AB, 179AB.

4Recommended course, not required.

(Not accredited by a Commission of ABET.)

1Students may take the slower paced version, CSE 8A-B, instead of CSE 11.

2Technical elective (TE) courses must be selected from a departmental approved list. Consult the Student Affairs Office.

3Ten HSS courses are listed here; individual college requirements may be higher.

4Design elective (DE) courses must be selected from a two-quarter sequence: BENG 119A-B, 126A-B, 127A-B, 128A-B, 129A-B, 139A-B, 147A-B, 148A-B, 149A-B, 169A-B, 179A-B.

Because of heavy student interest in the majors in the Department of Bioengineering and the limited resources available to accommodate this demand, maintenance of a high quality program makes it necessary to limit enrollments to the most qualified students.

Students admitted into a capped major who transfer out of the capped major may transfer back into it one time without meeting the full requirements for continuing student admission prior to the end of their sophomore year, provided they are in good academic standing.

Freshman students who have excelled in high school and have declared Bioengineering, Bioengineering: Biotechnology, Bioengineering: Bioinformatics, or Bioengineering: BioSystems on their UC San Diego application are eligible for direct admission into those majors.

The UC San Diego Office of Admissions and Relations with Schools will calculate an admissions target number and admit the appropriate number of incoming freshmen into each impacted major using the UC San Diego Holistic Review score as a ranking method. Students who meet the UC San Diego admission criteria will be admitted into their chosen capped major, starting with the student having the highest holistic review score, until the admission target number is reached. These students will be notified directly by the Office of Admissions and Relations with Schools whether they have been admitted into their chosen capped major.

Freshman students who applied but were not admitted directly from high school into the capped Bioengineering, Bioengineering: Biotechnology, Bioengineering: Bioinformatics, or Bioengineering: BioSystems majors will be admitted into the major indicated as their second choice on the UC application (providing it is an open major).

Each fall quarter, a certain number (determined on an annual basis) of continuing sophomore students who apply will be selected to enter the capped Bioengineering, Bioengineering: Biotechnology, Bioengineering: Bioinformatics, or Bioengineering: BioSystems majors. Interested continuing students must not be past sophomore standing, as time to graduation would be delayed since departmental upper-division courses are currently offered only once a year.

Continuing students will be required to complete the following courses prior to applying, depending on their major of choice:

Bioengineering and Bioengineering: Biotechnology: BILD 1; Chem 6A-B; MAE 8; Math 20A-C; Physics 2A-B.

Bioengineering: Bioinformatics: BILD 1; Chem 6A-B; CSE 11 (or 8A-B); Math 20A-C; Phys 2A-B.

Bioengineering: BioSystems: ECE 35; Chem 6A-B; Math 20A-C, Phys 2A-B.

Students will receive e-mail instructions from the Bioengineering Student Affairs Office concerning completion of an online application at the beginning of fall quarter of their second year. Online applications must be submitted by Friday of the first week of instruction in fall quarter. Continuing students applications will be ranked according to the GPA obtained in the required courses only.

Applications to a capped major will be approved, starting with the student having the highest GPA in the required courses, until the predetermined target number is reached. The Bioengineering Student Affairs Office will notify students in a timely manner who are successful in transitioning into one of the capped majors to officially declare the appropriate major online via the Major/Minor link under Toolbox at http://tritonlink.ucsd.edu.

Continuing students who apply and are unable to transition into one of the capped majors will also be notified of their status in a timely manner by the Bioengineering Student Affairs Office.

General advice: Transfer students are advised to complete the following courses for their major before enrolling at UC San Diego. Preparing well for the major helps students move efficiently toward graduation.

The UC San Diego Office of Admissions and Relations with Schools will calculate an admissions target number and admit the appropriate number of incoming transfer students into each capped major, based on the community college GPA. Additionally, transfer students should have completed the following courses for admission equivalent to UC San Diego:

Bioengineering: Math 20A-B-C-D; Physics 2A-B and 2BL-CL; and Chemistry 6A-B

Bioengineering: Biotechnology: Math 20A-B-C-D; Physics 2A-B and 2CL; and Chemistry 6A-B

Bioengineering: Bioinformatics and Bioengineering: BioSystems: Math 20A-B-C-D; Physics 2A-B; and Chemistry 6A-B

Students who meet the UC San Diego admission criteria will be admitted into their chosen capped major, starting with the student having the highest community college GPA, until the admission target number is reached. (At least a 3.2 GPA in the community college transfer courses, and a 3.4 GPA in math, physics, and computer science courses, are likely to be needed to gain admission.) These students will be notified directly by the Office of Admissions and Relations with Schools whether they have been admitted into their chosen impacted major.

Transfer students who applied but were not admitted directly from community college into the capped Bioengineering, Bioengineering: Biotechnology, Bioengineering: Bioinformatics, or Bioengineering: BioSystems majors will be admitted into the major indicated as their second choice on the UC application (providing it is an open major).

Upon admission to a major, students are encouraged to seek advice from departmental staff in the Bioengineering Student Affairs Office, Room 141, Powell-Focht Bioengineering Hall, to plan a program of study. Students are expected to chart their progress within their major. As the department may make a small number of course and/or curricular changes every year, it is imperative that students check their e-mail for updates and consult a bioengineering undergraduate adviser on an annual basis.

To enroll in any courses required for a bioengineering major, a student must have completed prerequisite courses. (The department does not consider D or F grades as adequate preparation for subsequent material.) Where these prerequisite course work and other restrictions apply, the registrar will not enroll other students except by department approval. Students are advised that they may be dropped from course rosters if prerequisites have not been met.

Bioengineering courses are typically offered only once a year and therefore should be taken in the recommended sequence. If courses are taken out of sequence, it may not always be possible to enroll in courses as desired or needed for timely graduation. If this occurs, students should seek immediate departmental advice.

Programmatic advice may be obtained from the Student Affairs Office. In addition, technical advice may be obtained from a specific bioengineering faculty adviser assigned to each student upon admission to the major.

Exceptions to any program or course requirements are possible if approved by the Undergraduate Studies Committee before the courses in question are taken. Petitions may be obtained from the Bioengineering Student Affairs Office.

A capstone design course sequence is required for senior level students in the Bioengineering, Bioengineering: Biotechnology, and Bioengineering: BioSystems majors. The capstone design course sequence consists of a multiquarter upper-division sequence of courses that totals ten quarter-units and includes (1) a series of four one-unit courses on selection (BENG 187A), design (BENG 187B), implementation (BENG 187C), and presentation (BENG 187D) of design projects, with consideration of professional issues, and (2) a sequence of two three-unit laboratory design projects, offered in many of the primary areas of bioengineering, including biomechanics (BENG 119AB), systems bioengineering (BENG 127AB, 128AB, 129AB), nanoscale and molecular bioengineering (BENG 139AB), organ system bioengineering (BENG 147AB, 148AB, 149AB), tissue engineering and regenerative medicine (BENG 169AB), and bioinstrumentation (BENG 179AB). The design projects and presentations will be performed by student teams in the course sequence.

Under the guidance of a bioengineering faculty member, lower- and upper-division level bioengineering students have opportunities to participate in independent study and research.

Upper-division bioengineering students may take BENG 199, Independent Study for Undergraduates. Lower-division bioengineering students may enroll in BENG 99, which is similar to BENG 199 except that less background in the curriculum is needed. These courses are taken as electives on a P/NP basis. Under certain conditions, a BENG 199 course may be used to satisfy upper-division technical elective course requirements for the major. Students interested in this alternative must identify a faculty member with whom they wish to work and propose a two-quarter research or study topic for Bioengineering, Bioengineering: Biotechnology, and Bioengineering: BioSystems majors. Completion of two consecutive quarters of BENG 199 will satisfy both technical elective requirements in the Bioengineering, Bioengineering: Biotechnology, and Bioengineering: BioSystems majors. Bioengineering: Bioinformatics majors may satisfy up to two of the three technical elective requirements in those majors by completion of BENG 199 courses. After obtaining the faculty advisers concurrence on the topic and scope of the study, the student must submit a Special Studies form (each quarter) and a BENG 199 as Technical Elective Contract to the Undergraduate Studies Committee. These forms must be completed, approved, and processed prior to the beginning of the quarter in which the course is to be taken.

Students interested in participating in the instructional activities of the department may take BENG 195, Undergraduate Teaching as an elective on a P/NP basis. Policy in this regard may be obtained from the Student Affairs Office.

The Department of Bioengineering offers two industry-related programs: the Industrial Internship Program for undergraduates and the Graduate Industrial Training Program for graduate students. Both industrial programs are designed to complement the departments academic curriculum with practical industry experience. Students interested in these programs should contact the Bioengineering Student Affairs Office well in advance of the quarter in which they would like to start their internship.

The Industrial Internship Program is available to undergraduate students who have completed all lower-division course requirements. Academic credit under BENG 196, Bioengineering Industrial Internship, can be earned by spending ten weeks or more as interns in an industrial setting. The intern may be involved in a range of activities, including design, analysis, manufacturing, testing, regulatory affairs, etc., under the direction of a mentor in the workplace. At the completion of the internship experience, students are required to submit a brief report to the mentor and faculty adviser describing their activities. Up to four units of BENG 196 may be used towards technical elective credit.

The Graduate Industrial Training Program is designed for students in the Master of Engineering Degree Program. This program serves to significantly enhance the professional development of MEng students in preparation for leadership in the bioengineering industry. Students will complete an independent industrial bioengineering project in a company setting under the direction of an industrial and faculty adviser.

Original post:
Bioengineering - University of California, San Diego

The Moral Question That Stanford Asks Its Bioengineering Students – The Atlantic

When students in Stanford Universitys Introduction to Bioengineering course sit for their final exams, the first question that they have to answer is about our ability to write DNA.

Scientists have fully sequenced the genomes of humans, trees, octopuses, bacteria, and thousands of other species. But it may soon become possible to not just read large genomes but also to write themsynthesizing them from scratch. Imagine a music synthesizer with only four keys, said Stanford professor Drew Endy to the audience at the Aspen Ideas Festival, which is co-hosted by the Aspen Institute and The Atlantic. Each represents one of the four building blocks of DNAA, C, G, and T. Press the keys in sequence and you can print out whatever stretch of DNA you like.

In 2010, one group did this for a bacterium with an exceptionally tiny genome, crafting all million or so letters of its DNA and implanting it into a hollow cell. Another team is part-way through writing the more complex genome of bakers yeast, with 12 million letters. The human genome is 300 times bigger, and as I reported last month, others are trying to build the technology that will allow them to create genomes of this size.

For now, thats prohibitively expensive, but it wont always be that way. In 2003, it cost 4 dollars to press one of the keys on Endys hypothetical synthesizer. This month, it costs just two centsa 200-fold decrease in price in just 14 years. In the same time frame, the cost of tuition at Stanford has doubled, and is now around $50,000. Given all of that, the first question that Stanfords budding bioengineers get is this:

At what point will the cost of printing DNA to create a human equal the cost of teaching a student in Stanford?

And the answer is: 19 years from today.

There are a lot of assumptions built into that answer. It will take a lot of technological advances to print the complex genomes of humans and to keep the costs falling at the same pace as they have done. But bearing those assumptions in mind, the problem is a mathematical one, and the students are graded on their ability to solve it. But the follow-up question is a little more complicated:

If you and your future partner are planning to have kids, would you start saving money for college tuition, or for printing the genome of your offspring?

The question tends to split students down the line, says Endy. About 60 percent say that printing a genome is wrong, and flies against what it means to be a parent. They prize the special nature of education and would opt to save for the tuition. But around 40 percent of the class will say that the value of education may change in the future, and if genetic technology becomes mature, and allows them to secure advantages for them and their lineage, they might as well do that.

There is clearly no right answer to the second question, and students are graded on their reasoning rather than their conclusion. But when both questions are considered together, they suggest, Endy says, that in the order of a human generation, well have to face possibilities that are much stranger than what were prepared for.

Read the original post:
The Moral Question That Stanford Asks Its Bioengineering Students - The Atlantic

Visiongain Report Looks at Opportunities Within the $23bn Cell Therapy Technologies Market – PR Newswire UK

Cell Therapy Technologies Market Forecast 2020-2030

LONDON, March 25, 2020 /PRNewswire/ -- Consumables, Equipment, System & Software, Cell Processing, Cell Processing Equipment, Single Use Equipment, Cell Preservation, Distribution, Handling, Process Monitoring & Quality Control, Human Cells, Animal Cells, Life Sciences & Research Companies, Research Institutes

Visiongain estimates that the global cell therapy technologies market will grow at a CAGR of 15% in the first half of the forecast period. In 2020, North America is estimated to hold 38% of the global cell therapy technologies market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new201-page reportyou will receive104 tables and 110 figures all unavailable elsewhere.

The 201-page Visiongain report provides clear detailed insight into the cell therapy technologies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/cell-therapy-technologies-market-forecast-2020-2030/#download_sampe_div

Report Scope

Global Cell Therapy Technologies Marketfrom2020-2030

Forecast of the Global Cell Therapy Technologies Market byType of Product: Consumables Equipment:Cell Processing Equipment, Single Use Equipment, Other Equipment System & Software

Forecast of the Global Cell Therapy Technologies byProcess Type: Cell processing Cell preservation, distribution and handling Process monitoring and quality control

Forecast of the Global Cell Therapy Technologies byCell Type: Human cells:Stem cells, Differentiated cells Animal cells

Forecast of the Global Cell Therapy Technologies byEnd User: Life Sciences and Research Companies Research Institutes

This report provides individual revenue forecasts to 2030 for thesenational markets: The US Canada Mexico UK Germany France Italy Spain Japan China India South Korea Singapore Malaysia Russia Brazil Argentina UAE South Africa Nigeria Mexico

Our study discusses the selectedleading companiesthat are the major players in the respiratory inhalers market: GE Healthcare Lonza Group Merck KGaA Terumo Bct, Inc. Thermo Fisher Scientific, Inc. & Other Companies

For the leading companies, we feature product portfolios, business segment breakdowns, recent developments & key expansion strategies etc.

This report discussesfactors that drive and restrainthis market. As well asopportunitiesandchallengesfaced by this market.

This report discusses thePorter's Five Forces Analysisof the Cell Therapy Technologies Market.

Key questions answered by this report: How is the Cell Therapy Technologies Market evolving? What is driving and restraining factors of the Cell Therapy Technologies Market? What are the market shares of each segment of the overall Cell Therapy Technologies Market in 2020? How will each Cell Therapy Technologies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030? How will the market shares for each Cell Therapy Technologies submarket develop from 2021 to 2030? What will be the main driver for the overall market from 2021 to 2030? Will leading national Cell Therapy Technologies Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others? How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030? Who are the leading players and what are their prospects over the forecast period? How will the industry evolve during the period between 2020 and 2030?

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/cell-therapy-technologies-market-forecast-2020-2030/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

Affymetrix, Inc.AkouosAllCellsApplikon Biotechnology Inc.ATLATL CentreAutolus LimitedBeckman Coulter, Inc.Becton, Dickinson and CompanyBioengineering AGBiological IndustriesBioWa, IncBrammer BioC.R. Bard, Inc.CaridianBCT, IncCell and Gene Therapy Asia Technology CentreCentre for Process Innovation (CPI)CMC Biologics (Asahi Glass Co.)Cobra BiologicsCocoon PlatformCryoportDanaher CorporationDiNAQOR AGEMD Performance MaterialsEMD SeronoEppendorf AGEuropean Molecular Biology Laboratory (EMBL)Finesse Solutions, Inc.Flexsafe RM TXFloDesign SonicsFlowJo, LLCFood and Drug Administration (FDA)Gamida CellG-CON ManufacturingGE healthcareGenScriptInfors HTIntegrated DNA Technologies, Inc.LaVision BioTecLonza Group, GE HealthcareMassachusetts Eye and Ear (MEE)Meissner Filtration Products, Inc.Merck KGaAMerck SeronoMesoblastMilliporeSigmaMiltenyi BiotecNova BiomedicalPall Corporation (Pall)Patheon N.V.Penn State UniversityPharmaCell B.VSartorius AGSartorius Stedim BiotechScinogySelecta Biosciences, IncSiemensSolaris BiotechStafa Cellular TherapyStafaCTStemcell TechnologiesTerumo Bct, Inc. (A Subsidiary of Terumo Corporation)Thermo Fisher Scientific, Inc.Tillotts Pharma AGTranstem LabUniCAR TherapyWorld Courier

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Stem Cell Technologies and Applications Market 2019-2029

Biobanking Market Forecasts 2019-2029

Biologics Market Trends and Forecasts 2019-2029

Global Bioreactors Market 2020-2030

Global Precision Medicine Market Forecast 2019-2029

Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

SOURCE Visiongain

See original here:
Visiongain Report Looks at Opportunities Within the $23bn Cell Therapy Technologies Market - PR Newswire UK

Cysteine Industry Forecast and Growth Opportunities 2020-2025 | COVID-19 Impact | Wacker Chemie AG, Ajinomoto Pte.Ltd, Donboo Amino Acid Co. Ltd, Wuxi…

A new intelligence report Cysteine Market has been recently added to Adroit Market Research collection of top-line market research reports. Global Cysteine Market report is a meticulous all-inclusive analysis of the market that offers access to direct first-hand insights on the growth trail of market in near term and long term. On the basis of factual information sourced from authentic industry experts and extensive primary industry research, the report offers insights on the historic growth pattern of Cysteine Market and current market scenario. It then provides short- and long-term market growth projections.

Request Free Sample Report of Cysteine Market at: https://www.adroitmarketresearch.com/contacts/request-sample/304

Projections are purely based on the detailed analysis of key market dynamics that are expected to influence Cysteine Market performance and their intensity of impacting market growth over the course of assessment period.

In addition to evaluation of dynamics, the report provides in-depth examination of key industry trends that are expected to act more prominently in global Cysteine Market. The study also offers valued information about the existing and upcoming growth opportunities in Cysteine Market that the key players and new market entrants can capitalize on.

Competitive companies and manufacturers in global market

Wacker Chemie AG, Ajinomoto Pte.Ltd, Donboo Amino Acid Co. Ltd, Wuxi Bikang Bioengineering Co., Nippon Rika Co.Ltd, Merck and Co., Inc.

View Full Report at: https://www.adroitmarketresearch.com/industry-reports/cysteine-market

Opportunity assessment offered in this Cysteine Market report is important in terms of understanding the lucrative areas of investment, which prove to be the actionable insights for leading market players, suppliers, distributors, and other stakeholders in Cysteine Market.

In-depth global Cysteine Market taxonomy presented in this report provides detailed insights about each of the market segments and their sub-segments, which are categorized based on t par various parameters. An exhaustive regional analysis of global Cysteine Market breaks down global market landscape into key geographies.

Regional outlook and country-wise analysis of Cysteine Market allows for the evaluation of multi-faceted performance of market in all the key economies. This information intends to offer a broader scope of report to readers and identify the most relevant profitable areas in global market place.

Global Cysteine market is segmented based by type, application and region.

Based on Type, the market has been segmented into:

Based on source, l- cysteine is segmented into (Natural through feathers and human hair, Synthetic through microbial fermentation), Based on the grade, l- cysteine is segmented into (Food grade, Tech grade, Pharma grade), Based on the Industrial use, l- cysteine is segmented into(Food, Pharmaceuticals, Cosmetics)

Based on application, the market has been segmented into:

Based on Applications, l- cysteine is segmented into (Conditioner, Flavor enhancer, Reducing agent, Radical scavenger)

Key Regions and Countries Covered in Global Cysteine Market Report-1. North America (US)2. Europe (Germany, France, UK)3. Asia-Pacific (China, Japan, India)4. Latin America (Brazil)5. The Middle East & Africa

Taxonomy and geographical analysis of the global Cysteine Market enables readers to spot profits in existing opportunities and capture upcoming growth opportunities even before they approach the market place. The analysis offered in report is purely intended to unroll the economic, social, regulatory and political scenarios of the market specific to each region and country, which could help potential market entrants in Cysteine Market landscape to understand the nitty-gritty of target market areas and devise their strategies accordingly.

Cysteine Market Table of Contents1. Research Methodology2. Cysteine Market Overview3. Global Cysteine Market by Type4. Global Cysteine Market by application5. Global Cysteine Market by region6. Global Cysteine Market Production and Consumption Analysis By Region7. Market Determinants8. Global Cysteine Market Competition by Manufacturers9. Global Cysteine Market Manufacturers Analysis10. Cysteine Market Value Chain Analysis

Do you have any query or specific requirement? Ask to our industry expert at: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/304

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Go here to read the rest:
Cysteine Industry Forecast and Growth Opportunities 2020-2025 | COVID-19 Impact | Wacker Chemie AG, Ajinomoto Pte.Ltd, Donboo Amino Acid Co. Ltd, Wuxi...